Blood Cancer
Showing 17–32 of 49 results
-
GAZYVA (obinutuzumab) injection, for intravenous infusion. Initial U.S. Approval: 2013
Read more -
ICLUSIG (ponatinib) tablets for oral use. Initial U.S. Approval: 2012
Read more -
IDHIFA (enasidenib) tablets, for oral use. Initial U.S. Approval: 2017
Read more -
IMLYGIC (talimogene laherparepvec). Suspension for intralesional injection Initial U.S. Approval: 2015
Read more -
KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. Approval: 2014
Read more -
LIBTAYO (cemiplimab-rwlc) injection, for intravenous use. Initial U.S. Approval: 09/2018
Read more -
MEKINIST (trametinib) tablets, for oral use. Initial U.S. Approval: 2013
Read more -
MONJUVI (tafasitamab-cxix) for injection. FDA-Approved. To treat lymphoma
Read more -
MULPLETA (lusutrombopag tablets) for oral use. Initial U.S. Approval: 2018
Read more -
MYLOTARG (gemtuzumab ozogamicin) for injection, for intravenous use. Initial U.S. Approval: 2000
Read more -
NINLARO (ixazomib) capsules, for oral use. Initial U.S. Approval: 2015
Read more -
ONUREG (azacitidine) tablets, for oral use. Initial U.S. Approval: 2004
Read more -
OPDUALAG (nivolumab and relatlimab-rmbw) injection
Read more -
POLIVY (polatuzumab vedotin-piiq) for injection, for intravenous use. Initial U.S. Approval: 2019
Read more -
POMALYST (pomalidomide) capsules, for oral use. Initial US Approval: 2013
Read more -
PROMACTA (eltrombopag) for oral suspension Initial U.S. Approval: 2008
Read more